← boardnext 2027-10
EVMN
Evommune, Inc.distress 3/10 · well-funded / low risk$11.24-1%today-64% from 52w high
Dermatology 1Immunology / Inflammation 1
Lead: atopic dermatitis (AD) · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$307M
Runway
3.5 yrs
Shares 1y
+14%
Price & events
-40.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-4.0%
1W
-53.6%
1M
-56.5%
3M
-40.4%
6M
—
1Y
—
2Y
—
5Y
-44.4%
All
Overview
- Market Cap
- $405.03M
- Volume
- 15.88K
- 52 Week Range
- $11.24 – $31.57
- Total Shares
- 36.02M
- Float Shares
- 18.07M
- Short %
- 19.71%
- % Held by Insiders
- 3.18%
- % Held by Institutions
- 111.00%
- RVOL
- 0.01x
Pipeline stages · 2 programs
EVO756, Dose 1, Dose 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
EVO301
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | EVO756, Dose 1, Dose 2 | Migraine | — | recruiting |
| 2026-07 | Phase 2 | EVO756 | Atoptic Dermatitis | 120 | active not recruiting |
| 2026-06 | Phase 2 | EVO756 | Chronic Spontaneous Urticaria | 160 | active not recruiting |
| 2025-11-17 | Phase 2 | EVO301 | Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis | 71 | completed |
| 2025-05-08 | Phase 2 | Oral EVO756 300 mg QD, Oral EVO756 50 mg BID | Chronic Inducible Urticaria | 30 | completed |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 9
- 2027Guided 40%trial initiationsecondaryPhase 2EVO756 · Phase 2 trial initiation for EVO756 in other indicationsSEC 8-K
- 2027Guided 40%readoutPhase 2EVO756 · Top-line data from migraine prophylaxis trial anticipated in 2027SEC 8-K
- mid-2027Guided 55%trial initiationsecondaryPhase 2EVO301 · Initiate Phase 2b trial with subcutaneous formulation in ADSEC 8-K
- H2 2026Guided 55%readoutPhase 2EVO756 · Phase 2b data readout for EVO756 in atopic dermatitisSEC 8-K
- third quarter of 2026Guided 70%readoutPhase 2EVO756 · Top-line Phase 2b data readout in ADSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- June 2026readoutPhase 2EVO756 · Top-line Phase 2b data readout in CSUSEC 8-K
- mid-2026trial initiationsecondaryPhase 2EVO756 · Phase 2 trial initiation for EVO756 in migraineSEC 8-K
- May 13-16, 2026conferencedata presentationsecondaryEVO301 · Preclinical data at SID 2026 on IL-18 inhibition in ADSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $31 (+177% upside) · 7 analysts
- 2026-06-30HC Wainwright & Co.Buy → Neutral
- 2026-06-30Morgan StanleyOverweight
- 2026-06-29William BlairOutperform → Market Perform
- 2026-05-26HC Wainwright & Co.Buy
- 2026-05-11Morgan StanleyOverweight
- 2026-04-10RBC CapitalOutperform
Competitors — atopic dermatitis (AD)
- none identified
Recent news
- 2026-07-22Top Evommune (EVMN) Competitors 2026 - MarketBeat
- 2026-07-21Long term debt to total assets ratio of Evommune, Inc. – BX:EVMNUSD - TradingView
- 2026-07-18Evommune Inc. Q1 2026 Earnings: EPS Beat Exceeds Expectations Amid Pre-Revenue Phase - Surprise Factor Analysis - dars.gov.et
- 2026-07-16Clear Street Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $28 - Moomoo
- 2026-07-14Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
- 2026-07-11Insider Purchase: Chief Financial Officer of $EVMN Buys 1,000 Shares - Quiver Quantitative
- 2026-07-10Evommune (NYSE:EVMN) CFO Acquires 1,000 Shares of Stock - MarketBeat
- 2026-07-10Independent Director of Evommune Arthur Kirsch Buys More Stock - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.